Core Insights - Citius Oncology is expanding access to its oncology therapy LYMPHIR through Named Patient Programs (NPPs) in various regions, including Southern Europe and the Balkans, by partnering with Integris Pharma S.A. [1][3][5] - NPPs provide a pathway for patients with serious conditions to access innovative treatments before full market approval, bridging the gap between clinical trials and market introduction [2][4][10] - The company aims to enhance awareness and clinical adoption of LYMPHIR while establishing it as a global treatment standard [3][6] Company Overview - Citius Oncology is a biopharmaceutical company focused on developing targeted oncology therapies, with LYMPHIR being its primary asset approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL) [12] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, supported by robust intellectual property protections [12] Product Information - LYMPHIR (denileukin diftitox-cxdl) is a targeted immune therapy for relapsed or refractory CTCL, indicated for use in Stage I-III disease after at least one prior systemic therapy [7][10] - The therapy works by binding to IL-2 receptors on tumor cells and regulatory T-cells, leading to cell death and enhanced antitumor activity [8] Distribution Strategy - The exclusive distribution agreement with Integris Pharma S.A. will facilitate the delivery of LYMPHIR to patients in Greece, Cyprus, and several Balkan countries [1][5] - Citius Oncology is also in discussions with multiple distribution partners across the European Union, South America, and select Middle Eastern territories to ensure broader patient access [6]